103440-55-7

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl 2-iodo-6-methylbenzoate is utilized as a key intermediate in the synthesis of pharmaceutical products. Its presence in the molecular structure allows for the development of new drugs with specific therapeutic properties, contributing to advancements in medicinal chemistry.
Used in Agrochemical Production:
In the agrochemical industry, Methyl 2-iodo-6-methylbenzoate serves as a precursor for the production of various agrochemicals. Its chemical properties make it suitable for the creation of compounds that can be used in pest control and crop protection, enhancing agricultural productivity.
Used in Organic Chemistry Research:
Methyl 2-iodo-6-methylbenzoate is recognized for its potential as a versatile building block in organic chemistry. Researchers use it to explore new synthetic pathways and develop innovative organic compounds for a range of applications, from materials science to specialty chemicals.
Used in Industrial Applications:
Methyl 2-iodo-6-methylbenzoate's unique structure and reactivity make it valuable in industrial applications, where it can be employed in the production of various organic compounds. Its versatility allows for its use in a wide array of processes, contributing to the development of new products and technologies.

Upstream product

• 67-56-1 methanol 
• 52107-92-3 2-iodo-6-methylbenzoyl chloride 
• 54811-50-6 2-iodo-6-methylbenzoic acid 
• 74-88-4 methyl iodide 
• 4389-50-8 2-amino-6-methylbenzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 118-90-1 ortho-methylbenzoic acid 

Downstream Products

• 54811-50-6 2-iodo-6-methylbenzoic acid 
• 861840-51-9 methyl 2-(bromomethyl)-6-iodobenzoate 
• 1261794-19-7 (2-iodo-6-methylphenyl)methanol 
• 1365840-82-9 (2-ethenyl-6-methylphenyl)methanol 
• 1402897-13-5 methyl 2-[(E)-2-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)vinyl]-6-methylbenzoate 
• 179554-11-1 2-allyl-6-methylbenzaldehyde 
• 1393900-53-2 7-(2-(2-((4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)isoindolin-1-one 
• 1393901-28-4 tert-butyl 4-(4-((4-(2-(3-oxoisoindolin-4-yl)ethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate 
• 1393901-26-2 tert-butyl 4-(4-((4-((3-oxoisoindolin-4-yl)ethynyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate 

Relevant academic research and scientific papers

EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of receptor tyrosine kinase (RTK) proteins. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand which binds to an E3 ubiquitin ligase and on the other end a moiety which binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effectuate ubiquitination, and therefore, degradation (and inhibition) of the target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Heterocyclic compounds and uses thereof

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the isoquinolone entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described

FAK AND FLT3 INHIBITORS

The use of a compound of the formula (I): (Formula (I)) in the preparation of a medicament for treating Acute Myeloid Leukemia or a disease ameliorated by the inhibition of Flt3, or Flt3 and FAK.

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders

FAK INHIBITORS

A compound of the formula (I): where R1 or R2 is a cycle amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.

Synthesis of 2-substituted β-cyclodextrin derivatives with a hydrolytic activity against the organophosphorylester paraoxon

β-Cyclodextrin was substituted by an iodosobenzoic acid derivative to create a catalytic hydrolytic activity against neurotoxic organophosphorus agents. The catalytic moiety was introduced on a secondary hydroxy group at the position 2 of a glucose unit.